SRX sierra rutile holdings limited

yttrium-90 radioembolization with glass microspheres

  1. 8,918 Posts.
    lightbulb Created with Sketch. 32
    In the interests of understanding both variants of SIRT. Conclusion is probably not too much different to SRX SIRT.

    http://www.sciencedirect.com/science/article/pii/S1120179716308353
    Optimization of activity and absorbed doses calculation to target/tumor and normal liver volumes in patients submitted to yttrium-90 radioembolization with glass microspheres.

    Introduction

    The model provided by manufacturers of the Y-90 microspheres does not consider dose restrictions to tumor and to normal liver volumes, but simply calculates activity to be administered based on a prescribed dose of 120 Gy corrected for liver volumes and hepato-pulmonary shunt. It is paramount to analyze data post Y-90 injection, creating dose volume histograms (DVH), to calculate the real absorbed dose distribution in liver segments with and without tumor.
    Purpose

    To investigate new algorithms to calculate activities during Y-90 glass microspheres liver radioembolization and optimizing absorbed doses to tumor/target and normal liver volumes.
    Materials and methods

    This is a retrospective study of eleven patients with multiple colorectal liver metastases submitted to liver radioembolization with Y-90 glass microspheres (TherasphereTM). CT and Y-90 PET images were used together with StratosTM software to obtain values for absorbed doses (based on distribution of Y-90) throughout the entire liver volume. Dose volume histograms (DVH) were created to stratify absorbed dose as percentage of total irradiated volume.
    Results

    Our results reveal that only 7% of the liver volume received twice and/or trice the intended prescribed dose of 120 Gy. 25% and 68% of the liver volume received respectively 120 and less than 50 Gy. All patients receiving less than 80 Gy in more than 50% of the liver volume are alive and well.
    Conclusion

    Our data suggest a relationship between patient clinical outcome and absorbed doses in liver volumes. Work to optimize administered activities according to tumor/target and normal liver volumes is underway.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.